anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Spyre Therapeutics · pitchdeck

Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides

37 pages · 4 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides

Spyre Therapeutics · 2023-10
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 17 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Solution 14 slides 100% 14/14 slides 100% 14/14 slides · 62 hits
— 0/14 slides
35.7% 5/14 slides 35.7% 5/14 slides 100% 14/14 slides 100% 14/14 slides · 15 hits Competition 1 slides 100% 1/1 slides 100% 1/1 slides · 3 hits
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides
— 0/1 slides
Team 1 slides 100% 1/1 slides 100% 1/1 slides · 5 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides

Slide inventory

37
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
The slide uses a horizontal bar chart to represent the development stage of each program.plan_implementation
Open slide detail
04
The slide uses a structured comparison layout to differentiate between individual programs and a combination strategy.present_solution
Open slide detail
05
The chart plots UC maintenance remission rates against maintenance dosing frequency, showing current standard-of-care drugs clustered at lower efficacy and highframe_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
06
The slide uses a three-column layout to present distinct technological approaches.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
07
The chart uses a horizontal bar representation to indicate progress through discovery and IND-enabling stages.plan_implementation
Open slide detailBeat · SolutionLoop · Golden Circle
08
The slide features a stylized antibody graphic overlaid on a dark blue/purple abstract background.front_matter
Open slide detailBeat · SolutionLoop · Golden Circle
09
present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
10
The slide uses a structural biology visualization and two dose-response curves to establish bio-equivalence and differentiation.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
11
The slide uses two semi-logarithmic line charts to compare drug concentration decay over time.show_traction
Open slide detailBeat · SolutionLoop · Golden Circle
12
summarize
Open slide detailBeat · SolutionLoop · Golden Circle
13
The slide uses a stepped process diagram to illustrate dose escalation cohorts.present_framework
Open slide detailBeat · SolutionLoop · Golden Circle
14
The slide uses a comparative bar chart approach to justify the human half-life prediction based on NHP data.analyze_data
Open slide detailBeat · SolutionLoop · Golden Circle
15
Uses icon-based visualization to represent injection frequency.compare_peers
Open slide detailBeat · SolutionLoop · Golden Circle
16
The slide uses a combination of a pharmacokinetic simulation line chart and a bar chart showing clinical remission rates by exposure quartile.analyze_data
Open slide detailBeat · SolutionLoop · Golden Circle
17
The slide uses a timeline-like visual to compare dosing schedules at weeks 0, 2, and 6.compare_peers
Open slide detailBeat · SolutionLoop · Golden Circle
18
The slide uses a comparative table for safety metrics and a bar chart for ADA rates to establish clinical equivalence/safety.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
19
summarize
Open slide detailBeat · SolutionLoop · Golden Circle
20
front_matter
Open slide detail
21
present_solution
Open slide detail
22
The funnel diagram illustrates the selection criteria: Monomer/Trimer binder -> Picomolar potency -> Extended half-life.present_solution
Open slide detail
23
The slide uses two distinct chart types to demonstrate potency (dose-response curve) and diversity (scatter plot of IC50 vs Relative DcR3/DR3 Blocking).show_traction
Open slide detail
24
compare_peers
Open slide detailBeat · Competition
25
summarize
Open slide detail
26
transition
Open slide detail
27
present_solution
Open slide detail
28
The slide uses a biological process diagram to illustrate the mechanism of action for three distinct therapeutic assets.present_solution
Open slide detail
29
The slide uses a stacked bar chart to visualize the additive clinical remission rates, noting a 22% delta between the individual components and the combination.compare_peers
Open slide detail
30
compare_peers
Open slide detail
31
summarize
Open slide detail
32
transition
Open slide detail
33
The slide includes a section for Management team and Board of Directors with headshots and titles, plus a logo grid at the bottom.other
Open slide detailBeat · Team
34
The slide uses a timeline-like structure to map clinical catalysts against expected timeframes.plan_implementation
Open slide detail
35
state_next_steps
Open slide detail
36
The slide details a corporate M&A event and subsequent private placement financing.summarize
Open slide detail
37
Includes a footnote regarding a 1-for-25 reverse stock split effective September 8, 2023.analyze_data
Open slide detail